Pierluigi Bove, MD, presented “Transperineal Laser Ablation versus Trans-Urethral Resection of Prostate for Benign Prostatic Obstruction: Results from a Randomized Clinical Trial” during the 42nd Annual Ralph E. Hopkins Urology Seminar on February 3, 2023, in Jackson Hole, Wyoming.
How to cite: Bove, Pierluigi “Transperineal Laser Ablation versus Trans-Urethral Resection of Prostate for Benign Prostatic Obstruction: Results from a Randomized Clinical Trial.” February 3, 2023. Accessed Nov 2024. https://grandroundsinurology.com/transperineal-laser-ablation-versus-trans-urethral-resection-of-prostate-for-benign-prostatic-obstruction-results-from-a-randomized-clinical-trial/
Transperineal Laser Ablation versus Trans-Urethral Resection of Prostate for Benign Prostatic Obstruction: Results from a Randomized Clinical Trial – Summary
Pierluigi Bove, MD, presents the methodology of a clinical trial, highlighting the inclusion criteria, randomization process, and primary and secondary endpoints. He emphasizes the study’s importance in addressing the clinical decision-making process for selecting the most appropriate surgical intervention for benign prostatic obstruction (BPO).
The results indicate that both transperineal laser ablation (TPLA) and transurethral resection of the prostate (TURP) significantly improve urinary flow rates and reduce symptom scores in patients with BPO. Dr. Bove notes that TPLA offers a less invasive alternative with a favorable safety profile, demonstrating lower rates of perioperative complications such as bleeding, infection, and urinary incontinence.
Dr. Bove delves into the long-term outcomes, comparing the durability of symptom relief and the need for retreatment between the two procedures. He highlights that while TURP remains the gold standard for BPO treatment, TPLA emerges as a promising technique with comparable efficacy and improved safety in certain patient populations.
About The 42nd Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 42nd iteration of the meeting took place from February 1st to 4th, 2023, in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Pierluigi Bove, MD, is an associate professor of urology at the Tor Vergata University of Rome in Italy. He graduated from the Tor Vergata University of Rome in medicine and surgery and earned a post-graduate degree in urology. Dr. Bove completed a research fellowship under Prof. Louis R. Kavoussi at the Johns Hopkins University School of Medicine’s James Buchanan Brady Urological Institute in Baltimore, Maryland. He completed a surgical fellowship under Prof. Fernando J. Kim at the University of Colorado Denver and a masterclass in laparoscopic radical prostatectomy under Prof. Guy Vallancien at the Université René Descartes in Paris, France. Dr. Bove earned a Second Level Master’s Degree in andrology at the University of Pisa in Italy and is qualified as a console surgeon for the da Vinci® surgical system.
Dr. Bove is a member of several scientific societies, including Società Italiana di Urologia (SIU), European Association of Urology (EAU), Italian Endourology Association (IEA) and Italian Group for Advanced Laparo-Endoscopic and Robotic Urologic Surgery (AGILE). He is author and co-author of approximately 150 scientific publications (H-index 28, www.scopus.com, last update October 2023); furthermore, he is the principal investigator for several scientific studies. He is a member of the scientific board of Associazione Italiana di Endourologia (IEA), Italian Group for Advanced Laparo‐Endoscopic Surgery (AGILE), Torvergata Oncoscience Research (TOR) group, Surgical Advisory Board Boston Scientific – Benign Prostatic Hyperplasia, and several multicentric research groups. Dr. Bove has performed over 4,500 major urological surgery procedures as first operator, primarily with a minimally invasive approach (pure laparoscopic or robot-assisted).
